Central nervous system stimulants are established treatments for pediatric attention-deficit/hyperactivity disorder with robust efficacy data. Reductions in appetite, weight, and growth velocity are some of the most common concerns regarding the long-term use of central nervous system stimulants in developing children. They are associated with suppression of weight and body mass index in childhood. However, both weight and body mass index often progressively increase over adolescence at rates faster than those seen in non-attention-deficit/hyperactivity disorder youth to the degree that attention-deficit/hyperactivity disorder is associated with elevated body mass index by the end of adolescence regardless of medication use. The capacity of central nervous system stimulants to slow growth was identified 50 years ago. Recent work has established that the growth deficits accumulate during the first 2 years of use and may persist provided medication is used. Early initiation coupled with persistent use through adolescence is most likely to be associated with clinical impactful growth suppression. There has been limited formal investigation of treatments for stimulant-associated reductions in weight and height. The most robust evidence exists for drug holidays improving weight gain. Observational studies suggest that limiting lifetime exposure or discontinuing medication is associated with greater adult height. Additional research is needed to identify the causal mechanisms driving the observed slowing in growth as well as the identification of predictors of clinically impactful growth suppression.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164(6):942–8.
Hales CM, Kit BK, Gu Q, Ogden CL. Trends in prescription medication use among children and adolescents: United States, 1999–2014. JAMA. 2018;319(19):2009–20.
Raman SR, Man KKC, Bahmanyar S, Berard A, Bilder S, Boukhris T, et al. Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases. Lancet Psychiatry. 2018;5(10):824–35.
Frank E, Ozon C, Nair V, Othee K. Examining why patients with attention-deficit/hyperactivity disorder lack adherence to medication over the long term: a review and analysis. J Clin Psychiatry. 2015;76(11):e1459–68.
Charach A, Ickowicz A, Schachar R. Stimulant treatment over five years: adherence, effectiveness, and adverse effects. J Am Acad Child Adolesc Psychiatry. 2004;43(5):559–67.
Rockhill CM. Editorial: a spoonful of injury prevention makes the ADHD medicine go down. J Am Acad Child Adolesc Psychiatry. 2020;59(8):920–2.
Brinkman WB, Simon JO, Epstein JN. Reasons why children and adolescents with attention-deficit/hyperactivity disorder stop and restart taking medicine. Acad Pediatr. 2018;18(3):273–80.
Arnold LE, Hodgkins P, Caci H, Kahle J, Young S. Effect of treatment modality on long-term outcomes in attention-deficit/hyperactivity disorder: a systematic review. PLoS ONE. 2015;10(2):e0116407.
DosReis S, Myers MA. Parental attitudes and involvement in psychopharmacological treatment for ADHD: a conceptual model. Int Rev Psychiatry. 2008;20(2):135–41.
Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002;41(2 Suppl.):26S-49S.
Pliszka S, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894–921.
National Institute for Health and Care Excellence (NICE). Attention deficit hyperactivity disorder: diagnosis and management. NICE Clinical Guideline CG87. London: NICE. 2018. http://www.nice.org.uk/guidance/ng87. Accessed 1 Aug 2021.
Barkley RA, McMurray MB, Edelbrock CS, Robbins K. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics. 1990;86(2):184–92.
Schachter HM, Pham B, King J, Langford S, Moher D. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ. 2001;165(11):1475–88.
Cortese S, Holtmann M, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, et al. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry. 2013;54(3):227–46.
Gillberg C, Melander H, von Knorring AL, Janols LO, Thernlund G, Hägglöf B, et al. Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry. 1997;54(9):857–64.
Zachor DA, Roberts AW, Hodgens JB, Isaacs JS, Merrick J. Effects of long-term psychostimulant medication on growth of children with ADHD. Res Dev Disabil. 2006;27(2):162–74.
Vitiello B, Severe JB, Greenhill LL, Arnold LE, Abikoff HB, Bukstein OG, et al. Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. J Am Acad Child Adolesc Psychiatry. 2001;40(2):188–96.
Safer D, Allen R, Barr E. Depression of growth in hyperactive children on stimulant drugs. N Engl J Med. 1972;287(5):217–20.
Faraone SV, Giefer EE. Long-term effects of methylphenidate transdermal delivery system treatment of ADHD on growth. J Am Acad Child Adolesc Psychiatry. 2007;46(9):1138–47.
Wilens T, McBurnett K, Stein M, Lerner M, Spencer T, Wolraich M. ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry. 2005;44(10):1015–23.
Biederman J, Krishnan S, Zhang Y, McGough JJ, Findling RL. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther. 2007;29(3):450–63.
Lage M, Hwang P. Effect of methylphenidate formulation for attention deficit hyperactivity disorder on patterns and outcomes of treatment. J Child Adolesc Psychopharmacol. 2004;14(4):575–81.
McGough JJ, Biederman J, Wigal SB, Lopez FA, McCracken JT, Spencer T, et al. Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2005;44(6):530–8.
The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry. 1999;56(12):1073–86.
Greenhill LL, Swanson JM, Hechtman L, Waxmonsky J, Arnold LE, Molina BSG, et al. Trajectories of growth associated with long-term stimulant medication in the Multimodal Treatment Study of Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry. 2020;59(8):978–89.
Swanson JM, Arnold LE, Molina BSG, Sibley MH, Hechtman LT, Hinshaw SP, et al. Young adult outcomes in the follow-up of the multimodal treatment study of attention-deficit/hyperactivity disorder: symptom persistence, source discrepancy, and height suppression. J Child Psychol Psychiatry. 2017;58(6):663–78.
Swanson J, Greenhill L, Wigal T, Kollins S, Stehli A, Davies M, et al. Stimulant-related reductions of growth rates in the PATS. J Am Acad Child Adolesc Psychiatry. 2006;45(11):1304–13.
Poulton A. Effect of long-term treatment with stimulant medication on growth? J Am Acad Child Adolesc Psychiatry. 2007;46(3):305.
Waxmonsky JG, Pelham WE, Campa A, Waschbusch DA, Li T, Marshall R, et al. A randomized controlled trial of interventions for growth suppression in children with attention-deficit/hyperactivity disorder treated with central nervous system stimulants. J Am Acad Child Adolesc Psychiatry. 2020;59(12):1330–41.
Wolraich ML, Hagan JF, Allan C, Chan E, Davison D, Earls M, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2020;145(3):e20193997.
Carucci S, Balia C, Gagliano A, Lampis A, Buitelaar JK, Danckaerts M, et al. Long term methylphenidate exposure and growth in children and adolescents with ADHD: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2021;120:509–25.
Satterfield JH, Cantwell DP, Schell A, Blaschke T. Growth of hyperactive children treated with methylphenidate. Arch Gen Psychiatry. 1979;36(2):212–7.
Poulton A, Cowell CT. Slowing of growth in height and weight on stimulants: a characteristic pattern. J Paediatr Child Health. 2003;39(3):180–5.
Mattes JA, Gittelman R. Growth of hyperactive children on maintenance regimen of methylphenidate. Arch Gen Psychiatry. 1983;40(3):317–21.
Poulton AS, Bui Q, Melzer E, Evans R. Stimulant medication effects on growth and bone age in children with attention-deficit/hyperactivity disorder: a prospective cohort study. Int Clin Psychopharmacol. 2016;31(2):93–9.
Powell SG, Frydenberg M, Thomsen PH. The effects of long-term medication on growth in children and adolescents with ADHD: an observational study of a large cohort of real-life patients. Child Adolesc Psychiatry Ment Health. 2015;9:1–3.
Spencer TJ, Biederman J, Harding M, O’Donnell D, Faraone SV, Wilens TE. Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays? J Am Acad Child Adolesc Psychiatry. 1996;35(11):1460–9.
Spencer T, Biederman J, Wilens T. Growth deficits in children with attention deficit hyperactivity disorder. Pediatrics. 1998;102(3):501–6.
Kramer JR, Loney J, Ponto LB, Roberts MA, Grossman S. Predictors of adult height and weight in boys treated with methylphenidate for childhood behavior problems. J Am Acad Child Adolesc Psychiatry. 2000;39(4):517–24.
The MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics. 2004;113(4):754–61.
Swanson JM, Elliott GR, Greenhill LL, Wigal T, Arnold LE, Vitiello B, et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry. 2007;46(8):1015–27.
Spencer TJ, Faraone SV, Biederman J, Lerner M, Cooper KM, Zimmerman B, et al. Does prolonged therapy with a long-acting stimulant suppress growth in children with ADHD? J Am Acad Child Adolesc Psychiatry. 2006;45(5):527–37.
Faraone SV, Biederman J, Monuteaux M, Spencer T. Long-term effects of extended-release mixed amphetamine salts treatment of attention- deficit/hyperactivity disorder on growth. J Child Adolesc Psychopharmacol. 2005;15(2):191–202.
Khwaja O. Drappatz J, Neovious M, Sarco D. Growth in children with ADHD treated with stimulant medications: a meta-analysis. Scientific Proceedings of the Pediatric Academic Societies; 29 April–2 May, 2006; San Francisco (CA): p. 458.
Pliszka SR, Matthews TL, Braslow KJ, Watson MA. Comparative effects of methylphenidate and mixed salts amphetamine on height and weight in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006;45(5):520–6.
Faraone SV, Biederman J, Morley CP, Spencer TJ. Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry. 2008;47(9):994–1009.
Ross L, Sapre V, Stanislaus C, Poulton AS. Dose adjustment of stimulants for children with attention-deficit/hyperactivity disorder: a retrospective chart review of the impact of exceeding recommended doses. CNS Drugs. 2020;34(6):643–9.
Charach A, Figueroa M, Chen S, Ickowicz A, Schachar R. Stimulant treatment over 5 years: effects on growth. J Am Acad Child Adolesc Psychiatry. 2006;45(4):415–21.
Landgren M, Nasic S, Johnson M, Lövoll T, Holmgren D, Fernell E. Blood pressure and anthropometry in children treated with stimulants: a longitudinal cohort study with an individual approach. Neuropsychiatr Dis Treat. 2017;13:499–506.
Eysbouts Y, Poulton A, Salmelainen P. Stimulant medication in pre-school children in New South Wales. J Paediatr Child Health. 2011;47(12):870–4.
Schertz M, Adesman AR, Alfieri NE, Bienkowski RS. Predictors of weight loss in children with attention deficit hyperactivity disorder treated with stimulant medication. Pediatrics. 1996;98(4):763–9.
Waxmonsky JG, Pelham WE, Baweja R, Pelham WE. Predictors of growth suppression in children with ADHD treated with central nervous system stimulants. In: Scientific Proceedings of the American Academy of Child and Adolescent Psychiatry Virtual Annual Meeting; October 2020.
Durá-Travé T, Yoldi-Petri ME, Gallinas-Victoriano F, Zardoya-Santos P. Effects of osmotic-release methylphenidate on height and weight in children with attention-deficit hyperactivity disorder (ADHD) following up to four years of treatment. J Child Neurol. 2012;27(5):604–9.
Lisska MC, Rivkees SA. Daily methylphenidate use slows the growth of children: a community based study. J Pediatr Endocrinol Metab. 2003;16(5):711–8.
Klein RG, Mannuzza S. Hyperactive boys almost grown up. III. Methylphenidate effects on ultimate height. Arch Gen Psychiatry. 1988;45(12):1131–4.
Biederman J, Spencer TJ, Monuteaux MC, Faraone SV. A naturalistic 10-year prospective study of height and weight in children with attention-deficit hyperactivity disorder grown up: sex and treatment effects. J Pediatr. 2010;157(4):635–40.
Peyre H, Hoertel N, Cortese S, Acquaviva E, Limosin F, Delorme R. Long-term effects of ADHD medication on adult height: results from the NESARC. J Clin Psychiatry. 2013;74(11):1123–4.
McCarthy S, Neubert A, Man KKC, Banaschewski T, Buitelaar J, Carucci S, et al. Effects of long-term methylphenidate use on growth and blood pressure: results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS). BMC Psychiatry. 2018;18(1):327.
Harstad EB, Weaver AL, Katusic SK, Colligan RC, Kumar S, Chan E, et al. ADHD, stimulant treatment, and growth: a longitudinal study. Pediatrics. 2014;134(4):e935–44.
Granato MF, Ferraro AA, Lellis DM, Casella EB. Associations between attention-deficit hyperactivity disorder (ADHD) treatment and patient nutritional status and height. Behav Neurol. 2018;2018:7341529.
Swanson J. Long term effects of stimulants in children with ADHD. Annual Meeting of the American Psychiatric Association; 2008; Washington, DC.
Poulton A. Growth on stimulant medication; clarifying the confusion: a review. Arch Dis Child. 2005;90(8):801–6.
Díez-Suárez A, Vallejo-Valdivielso M, Marín-Méndez JJ, de Castro-Manglano P, Soutullo CA. Weight, height, and body mass index in patients with attention-deficit/hyperactivity disorder treated with methylphenidate. J Child Adolesc Psychopharmacol. 2017;27(8):723–30.
Schwartz BS, Bailey-Davis L, Bandeen-Roche K, Pollak J, Hirsch AG, Nau C, et al. Attention deficit disorder, stimulant use, and childhood body mass index trajectory. Pediatrics. 2014;133(4):668–76.
Rapport MD, Moffitt C. Attention deficit/hyperactivity disorder and methylphenidate: a review of height/weight, cardiovascular, and somatic complaint side effects. Clin Psychol Rev. 2002;22(8):1107–31.
Prince JB. Pharmacotherapy of attention-deficit hyperactivity disorder in children and adolescents: update on new stimulant preparations, atomoxetine, and novel treatments. Child Adolesc Psychiatr Clin N Am. 2006;15(1):13–50.
Spencer TJ, Abikoff HB, Connor DF, Biederman J, Pliszka SR, Boellner S, et al. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: a 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study. Clin Ther. 2006;28(3):402–18.
Safer DJ, Allen RP, Barr E. Growth rebound after termination of stimulant drugs. J Pediatr. 1975;86(1):113–6.
Klein RG, Landa B, Mattes JA, Klein DF. Methylphenidate and growth in hyperactive children. A controlled withdrawal study. Arch Gen Psychiatry. 1988;45(12):1127–30.
Martins S, Tramontina S, Polanczyk G, Eizirik M, Swanson JM, Rohde LA. Weekend holidays during methylphenidate use in ADHD children: a randomized clinical trial. J Child Adolesc Psychopharmacol. 2004;14(2):195–206.
Daviss WB, Scott J. A chart review of cyproheptadine for stimulant-induced weight loss. J Child Adolesc Psychopharmacol. 2004;14(1):65–73.
Riahi F, Tashakori A, Vanani GS. Effects of folic acid on appetite in children with attention deficit hyperactivity disorder (ADHD) treated with methylphenidate: a randomized double-blind clinical trial. Iran J Med Sci. 2018;43(1):9–17.
Poulton AS, Melzer E, Tait PR, Garnett SP, Cowell CT, Baur LA, et al. Growth and pubertal development of adolescent boys on stimulant medication for attention deficit hyperactivity disorder. Med J Aust. 2013;198(1):29–32.
Modan-Moses D, Yaroslavsky A, Pinhas-Hamiel O, Levy-Shraga Y, Kochavi B, Iron-Segev S, et al. Prospective longitudinal assessment of linear growth and adult height in female adolescents with anorexia nervosa. J Clin Endocrinol Metab. 2021;106(1):e1-10.
Waring ME, Lapane KL. Overweight in children and adolescents in relation to attention-deficit/hyperactivity disorder: results from a national sample. Pediatrics. 2008;122(1):e1-6.
Cortese S, Moreira Maia CR, Rohde LA, Morcillo-Peñalver C, Faraone SV. Prevalence of obesity in attention-deficit/hyperactivity disorder: study protocol for a systematic review and meta-analysis. BMJ Open. 2014;4(3):e004541.
Cortese S. The association between ADHD and obesity: intriguing, progressively more investigated, but still puzzling. Brain Sci. 2019;9(10):256.
Mustillo S, Worthman C, Erkanli A, Keeler G, Angold A, Costello EJ. Obesity and psychiatric disorder: developmental trajectories. Pediatrics. 2003;111(4):851–9.
Pauli-Pott U, Neidhard J, Heinzel-Gutenbrunner M, Becker K. On the link between attention deficit/hyperactivity disorder and obesity: do comorbid oppositional defiant and conduct disorder matter? Eur Child Adolesc Psychiatry. 2014;23(7):531–7.
Efron D, Gulenc A, Sciberras E, Ukoumunne OC, Hazell P, Anderson V, et al. Prevalence and predictors of medication use in children with attention-deficit/hyperactivity disorder: evidence from a community-based longitudinal study. J Child Adolesc Psychopharmacol. 2019;29(1):50–7.
Bowling AB, Tiemeier HW, Jaddoe VW, Barker ED, Jansen PW. ADHD symptoms and body composition changes in childhood: a longitudinal study evaluating directionality of associations. Pediatr Obes. 2018;13(9):567–75.
Khalife N, Kantomaa M, Glover V, Tammelin T, Laitinen J, Ebeling H, et al. Childhood attention-deficit/hyperactivity disorder symptoms are risk factors for obesity and physical inactivity in adolescence. J Am Acad Child Adolesc Psychiatry. 2014;53(4):425–36.
Hechtman L, Weiss G, Perlman T. Young adult outcome of hyperactive children who received long-term stimulant treatment. J Am Acad Child Adolesc Psychiatry. 1984;23(3):261–9.
Poulton AS, Nanan R. Prior treatment with stimulant medication: a much neglected confounder of studies of growth in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2008;18(4):385–7.
Frindik JP, Morales A, Fowlkes J, Kemp S, Thrailkill K, Lippe B, et al. Stimulant medication use and response to growth hormone therapy: an NCGS database analysis. Horm Res. 2009;72(3):160–6.
Rao JK, Julius JR, Breen TJ, Blethen SL. Response to growth hormone in attention deficit hyperactivity disorder: effects of methylphenidate and pemoline therapy. Pediatrics. 1998;102(3):497–500.
Hermanussen M. Auxology: an update. Horm Res Paediatr. 2010;74(3):153–64.
Tenore A, Tenore A. A pathophysiologic approach to growth problems in children with attention-deficit/hyperactivity disorder. Endocrinol Metabol Clin. 2012;41(4):761–84.
Vitiello B. Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function. Child Adolesc Psychiatr Clin N Am. 2008;17(2):459–74.
Poulton A, Briody J, McCorquodale T, Melzer E, Herrmann M, Baur LA, et al. Weight loss on stimulant medication: how does it affect body composition and bone metabolism? A prospective longitudinal study. Int J Pediatr Endocrinol. 2012;2012(1):1–9.
Silva N, Bullinger M, Sommer R, Rohenkohl A, Witt S, Quitmann J. Children’s psychosocial functioning and parents’ quality of life in paediatric short stature: the mediating role of caregiving stress. Clin Psychol Psychother. 2018;25(1):e107–18.
Haymond M, Kappelgaard A-M, Czernichow P, Biller BMK, Takano K, Kiess W, et al. Early recognition of growth abnormalities permitting early intervention. Acta Paediatr. 2013;102(8):787–96.
Barstow C, Rerucha CM. Evaluation of short and tall stature in children. Am Fam Physician. 2015;92(1):43–50.
Ibrahim K, Donyai P. Drug holidays from ADHD medication: international experience over the past four decades. J Atten Disord. 2015;19(7):551–68.
Kaffman M, Sher A, Bar-Sinai N. MBD children: variability in developmental patterns or growth inhibitory effect of stimulants? Isr Ann Psychiatr Relat Discip. 1979;17(1):58–66.
Hanć T, Cieślik J. Growth in stimulant-naive children with attention-deficit/hyperactivity disorder using cross-sectional and longitudinal approaches. Pediatrics. 2008;121(4):e967–74.
Mei Z, Grummer-Strawn LM, Thompson D, Dietz WH. Shifts in percentiles of growth during early childhood: analysis of longitudinal data from the California Child Health and Development Study. Pediatrics. 2004;113(6):e617–27.
Marcus SC, Wan GJ, Kemner JE, Olfson M. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med. 2005;159(6):572–8.
Spencer TJ, Kratochvil CJ, Sangal RB, Saylor KE, Bailey CE, Dunn DW, et al. Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment. J Child Adolesc Psychopharmacol. 2007;17(5):689–700.
Germinario EA, Arcieri R, Bonati M, Zuddas A, Masi G, Vella S, et al. Attention-deficit/hyperactivity disorder drugs and growth: an Italian prospective observational study. J Child Adolesc Psychopharmacol. 2013;23(7):440–7.
Huss M, Dirks B, Gu J, Robertson B, Newcorn JH, Ramos-Quiroga JA. Long-term safety and efficacy of guanfacine extended release in children and adolescents with ADHD. Eur Child Adolesc Psychiatry. 2018;27(10):1283–94.
Biederman J, Melmed RD, Patel A, McBurnett K, Konow J, Lyne A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics. 2008;121(1):e73-84.
Wilens TE, Bukstein O, Brams M, Cutler AJ, Childress A, Rugino T, et al. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2012;51(1):74-85.e2.
Krugman SD, Dubowitz H. Failure to thrive. Am Fam Physician. 2003;68(5):879–84.
Ray WA, Stein CM, Murray KT, Fuchs DC, Patrick SW, Daugherty J, et al. Association of antipsychotic treatment with risk of unexpected death among children and youths. JAMA Psychiat. 2019;76(2):162–71.
Verhaegen AA, Van Gaal LF. Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options. J Endocrinol Investig. 2017;40(11):1165–74.
Pelham WE, Burrows-MacLean L, Gnagy EM, Fabiano GA, Coles EK, Wymbs BT, et al. A dose-ranging study of behavioral and pharmacological treatment in social settings for children with ADHD. J Abnorm Child Psychol. 2014;42(6):1019–31.
Coles EK, Pelham WE, Fabiano GA, Gnagy EM, Burrows-MacLean L, Wymbs BT, et al. Randomized trial of first-line behavioral intervention to reduce need for medication in children with ADHD. J Clin Child Adolesc Psychol. 2020;49(5):673–87.
No sources of funding were used to assist with the preparation of this review.
Conflict of interest
James G. Waxmonsky has received research funding from the National Institutes of Health, Supernus, and Pfizer in the past 3 years. Raman Baweja and Daniel E. Hale report no biomedical financial interests or potential conflicts of interest that are directly relevant to the content of this article.
Consent to participate
Consent for publication
Availability of data and material
RB provided the concept, performed the literature search, and drafted the initial version of the manuscript. DH and JW provided the concept and critically revised the work. All authors contributed to the final manuscript, approved the final version of the manuscript for publication, and agree to be accountable for the review.
About this article
Cite this article
Baweja, R., Hale, D.E. & Waxmonsky, J.G. Impact of CNS Stimulants for Attention-Deficit/Hyperactivity Disorder on Growth: Epidemiology and Approaches to Management in Children and Adolescents. CNS Drugs 35, 839–859 (2021). https://doi.org/10.1007/s40263-021-00841-w